Lista de obras - Mark T Orr - Dominio Público Uruguay

'Unlicensed' natural killer cells dominate the response to cytomegalovirus infection

artículo científico publicado en 2010

A dual TLR agonist adjuvant enhances the immunogenicity and protective efficacy of the tuberculosis vaccine antigen ID93.

scientific article published on 03 January 2014

A structure-function approach to optimizing TLR4 ligands for human vaccines

artículo científico publicado en 2016

AS03 stresses out macrophages: Commentary on ‘Activation of the endoplasmic reticulum stress sensor IRE1α by the vaccine adjuvant AS03 contributes to its immunostimulatory properties’.

artículo científico publicado en 2018

Adjuvant composition and delivery route shape immune response quality and protective efficacy of a recombinant vaccine for Entamoeba histolytica.

artículo científico publicado en 2018

Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis

artículo científico publicado en 2013

Adsorption of a synthetic TLR7/8 ligand to aluminum oxyhydroxide for enhanced vaccine adjuvant activity: A formulation approach

artículo científico publicado en 2016

Antigen presentation by B cells guides programing of memory CD4+ T-cell responses to a TLR4-agonist containing vaccine in mice

artículo científico publicado en 2016

Assessment of Antigen-Specific Cellular Immunogenicity Using Intracellular Cytokine Staining, ELISpot, and Culture Supernatants

artículo científico publicado en 2017

CD8 T cell control of HSV reactivation from latency is abrogated by viral inhibition of MHC class I

artículo científico publicado en 2007

CD94 is essential for NK cell-mediated resistance to a lethal viral disease

artículo científico publicado en 2011

Cutting edge: recombinant Listeria monocytogenes expressing a single immune-dominant peptide confers protective immunity to herpes simplex virus-1 infection

artículo científico publicado en 2007

Development and function of CD94-deficient natural killer cells

artículo científico publicado en 2010

Development of a thermostable nanoemulsion adjuvanted vaccine against tuberculosis using a design-of-experiments approach.

artículo científico publicado en 2018

Effective Combination Adjuvants Engage Both TLR and Inflammasome Pathways To Promote Potent Adaptive Immune Responses

article

Elimination of the cold-chain dependence of a nanoemulsion adjuvanted vaccine against tuberculosis by lyophilization

scientific article published on 29 December 2013

Enhanced Anti-Mycobacterium tuberculosis Immunity over Time with Combined Drug and Immunotherapy Treatment.

artículo científico publicado en 2018

Enzymatic Conversion of Sucrose to Hydrogen

article

Enzymatic production of biohydrogen

artículo científico publicado en 2000

From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE.

artículo científico publicado en 2015

IL-18 and Subcapsular Lymph Node Macrophages are Essential for Enhanced B Cell Responses with TLR4 Agonist Adjuvants.

artículo científico publicado en 2016

Immune subdominant antigens as vaccine candidates against Mycobacterium tuberculosis

artículo científico publicado en 2014

Inhibition of MHC class I is a virulence factor in herpes simplex virus infection of mice

artículo científico publicado en 2005

Inhibitory Ly49 receptors on mouse natural killer cells

scientific article published on January 2011

Interferon γ and Tumor Necrosis Factor Are Not Essential Parameters of CD4+ T-Cell Responses for Vaccine Control of Tuberculosis

artículo científico publicado en 2015

Key roles of adjuvants in modern vaccines

artículo científico publicado en 2013

Ly49H signaling through DAP10 is essential for optimal natural killer cell responses to mouse cytomegalovirus infection

scientific article published on 30 March 2009

Mouse Ly49G2+ NK cells dominate early responses during both immune reconstitution and activation independently of MHC

artículo científico publicado en 2011

Mucosal delivery switches the response to an adjuvanted tuberculosis vaccine from systemic TH1 to tissue-resident TH17 responses without impacting the protective efficacy

artículo científico publicado en 2015

MyD88 and TRIF synergistic interaction is required for TH1-cell polarization with a synthetic TLR4 agonist adjuvant

scientific article published on 03 July 2013

Natural killer cell education and tolerance

artículo científico publicado en 2010

Natural killer cell licensing during viral infection

artículo científico publicado en 2011

Natural killer cells in NOD.NK1.1 mice acquire cytolytic function during viral infection and provide protection against cytomegalovirus

artículo científico publicado en 2010

Physicochemical structure of a polyacrylic acid stabilized nanoparticle alum (nanoalum) adjuvant governs TH1 differentiation of CD4+ T cells

scientific article published on 13 January 2020

Protection against tuberculosis with homologous or heterologous protein/vector vaccine approaches is not dependent on CD8+ T cells

scientific article published on 31 July 2013

Reprogramming the adjuvant properties of aluminum oxyhydroxide with nanoparticle technology

scholarly article by Mark T Orr et al published 2019 in npj Vaccines

Squalene emulsion potentiates the adjuvant activity of the TLR4 agonist, GLA, via inflammatory caspases, IL-18, and IFN-γ.

artículo científico publicado en 2014

T cell receptor revision does not solely target recent thymic emigrants

artículo científico publicado en 2003

The ID93 tuberculosis vaccine candidate does not induce sensitivity to purified protein derivative

artículo científico publicado en 2014

The TLR4 Agonist Vaccine Adjuvant, GLA-SE, Requires Canonical and Atypical Mechanisms of Action for TH1 Induction

artículo científico publicado en 2016

The TLR4 agonist adjuvant SLA-SE promotes functional mucosal antibodies against a parenterally delivered ETEC vaccine

scientific article published on 28 May 2019

The science of vaccine adjuvants: advances in TLR4 ligand adjuvants

artículo científico publicado en 2016

Therapeutic immunization against Mycobacterium tuberculosis is an effective adjunct to antibiotic treatment

artículo científico publicado en 2012

Vaccination Produces CD4 T Cells with a Novel CD154-CD40-Dependent Cytolytic Mechanism

artículo científico publicado en 2015

Vaccine Adjuvants a

αv Integrins regulate germinal center B cell responses through noncanonical autophagy

article

Lista de obras de Mark T Orr

'Unlicensed' natural killer cells dominate the response to cytomegalovirus infection

A dual TLR agonist adjuvant enhances the immunogenicity and protective efficacy of the tuberculosis vaccine antigen ID93.

A structure-function approach to optimizing TLR4 ligands for human vaccines

AS03 stresses out macrophages: Commentary on ‘Activation of the endoplasmic reticulum stress sensor IRE1α by the vaccine adjuvant AS03 contributes to its immunostimulatory properties’.

Adjuvant composition and delivery route shape immune response quality and protective efficacy of a recombinant vaccine for Entamoeba histolytica.

Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis

Adsorption of a synthetic TLR7/8 ligand to aluminum oxyhydroxide for enhanced vaccine adjuvant activity: A formulation approach

Antigen presentation by B cells guides programing of memory CD4+ T-cell responses to a TLR4-agonist containing vaccine in mice

Assessment of Antigen-Specific Cellular Immunogenicity Using Intracellular Cytokine Staining, ELISpot, and Culture Supernatants

CD8 T cell control of HSV reactivation from latency is abrogated by viral inhibition of MHC class I

CD94 is essential for NK cell-mediated resistance to a lethal viral disease

Cutting edge: recombinant Listeria monocytogenes expressing a single immune-dominant peptide confers protective immunity to herpes simplex virus-1 infection

Development and function of CD94-deficient natural killer cells

Development of a thermostable nanoemulsion adjuvanted vaccine against tuberculosis using a design-of-experiments approach.

Effective Combination Adjuvants Engage Both TLR and Inflammasome Pathways To Promote Potent Adaptive Immune Responses

Elimination of the cold-chain dependence of a nanoemulsion adjuvanted vaccine against tuberculosis by lyophilization

Enhanced Anti-Mycobacterium tuberculosis Immunity over Time with Combined Drug and Immunotherapy Treatment.

Enzymatic Conversion of Sucrose to Hydrogen

Enzymatic production of biohydrogen

From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE.

IL-18 and Subcapsular Lymph Node Macrophages are Essential for Enhanced B Cell Responses with TLR4 Agonist Adjuvants.

Immune subdominant antigens as vaccine candidates against Mycobacterium tuberculosis

Inhibition of MHC class I is a virulence factor in herpes simplex virus infection of mice

Inhibitory Ly49 receptors on mouse natural killer cells

Interferon γ and Tumor Necrosis Factor Are Not Essential Parameters of CD4+ T-Cell Responses for Vaccine Control of Tuberculosis

Key roles of adjuvants in modern vaccines

Ly49H signaling through DAP10 is essential for optimal natural killer cell responses to mouse cytomegalovirus infection

Mouse Ly49G2+ NK cells dominate early responses during both immune reconstitution and activation independently of MHC

Mucosal delivery switches the response to an adjuvanted tuberculosis vaccine from systemic TH1 to tissue-resident TH17 responses without impacting the protective efficacy

MyD88 and TRIF synergistic interaction is required for TH1-cell polarization with a synthetic TLR4 agonist adjuvant

Natural killer cell education and tolerance

Natural killer cell licensing during viral infection

Natural killer cells in NOD.NK1.1 mice acquire cytolytic function during viral infection and provide protection against cytomegalovirus

Physicochemical structure of a polyacrylic acid stabilized nanoparticle alum (nanoalum) adjuvant governs TH1 differentiation of CD4+ T cells

Protection against tuberculosis with homologous or heterologous protein/vector vaccine approaches is not dependent on CD8+ T cells

Reprogramming the adjuvant properties of aluminum oxyhydroxide with nanoparticle technology

Squalene emulsion potentiates the adjuvant activity of the TLR4 agonist, GLA, via inflammatory caspases, IL-18, and IFN-γ.

T cell receptor revision does not solely target recent thymic emigrants

The ID93 tuberculosis vaccine candidate does not induce sensitivity to purified protein derivative

The TLR4 Agonist Vaccine Adjuvant, GLA-SE, Requires Canonical and Atypical Mechanisms of Action for TH1 Induction

The TLR4 agonist adjuvant SLA-SE promotes functional mucosal antibodies against a parenterally delivered ETEC vaccine

The science of vaccine adjuvants: advances in TLR4 ligand adjuvants

Therapeutic immunization against Mycobacterium tuberculosis is an effective adjunct to antibiotic treatment

Vaccination Produces CD4 T Cells with a Novel CD154-CD40-Dependent Cytolytic Mechanism

Vaccine Adjuvants a

αv Integrins regulate germinal center B cell responses through noncanonical autophagy